bluebird bio, Inc. BLE.MU Stock
bluebird bio, Inc. Price Chart
bluebird bio, Inc. BLE.MU Financial and Trading Overview
| bluebird bio, Inc. stock price | 1.11 EUR |
| Previous Close | 3.56 EUR |
| Open | 3.59 EUR |
| Bid | 3.59 EUR x N/A |
| Ask | 3.66 EUR x N/A |
| Day's Range | 3.59 - 3.59 EUR |
| 52 Week Range | 2.65 - 7.89 EUR |
| Volume | 100 EUR |
| Avg. Volume | 14 EUR |
| Market Cap | 398.27M EUR |
| Beta (5Y Monthly) | 0.930281 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.59 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
BLE.MU Valuation Measures
| Enterprise Value | 326.71M EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 98.75237 |
| Price/Book (mrq) | 1.0752623 |
| Enterprise Value/Revenue | 81.009 |
| Enterprise Value/EBITDA | -2.203 |
Trading Information
bluebird bio, Inc. Stock Price History
| Beta (5Y Monthly) | 0.930281 |
| 52-Week Change | 14.30% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 7.89 EUR |
| 52 Week Low | 2.65 EUR |
| 50-Day Moving Average | 3.45 EUR |
| 200-Day Moving Average | 5.56 EUR |
BLE.MU Share Statistics
| Avg. Volume (3 month) | 14 EUR |
| Avg. Daily Volume (10-Days) | 10 EUR |
| Shares Outstanding | 106.41M |
| Float | 89.74M |
| Short Ratio | N/A |
| % Held by Insiders | 1.04% |
| % Held by Institutions | 70.26% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -3802.85% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -16.19% |
| Return on Equity (ttm) | -39.86% |
Income Statement
| Revenue (ttm) | 4.03M EUR |
| Revenue Per Share (ttm) | 0.05 EUR |
| Quarterly Revenue Growth (yoy) | 22.40% |
| Gross Profit (ttm) | -247244000 EUR |
| EBITDA | -148300000 EUR |
| Net Income Avi to Common (ttm) | -123186000 EUR |
| Diluted EPS (ttm) | -1.47 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 318.26M EUR |
| Total Cash Per Share (mrq) | 2.99 EUR |
| Total Debt (mrq) | 273.38M EUR |
| Total Debt/Equity (mrq) | 77.06 EUR |
| Current Ratio (mrq) | 3.028 |
| Book Value Per Share (mrq) | 3.335 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -314295008 EUR |
| Levered Free Cash Flow (ttm) | -118386624 EUR |
Profile of bluebird bio, Inc.
| Country | Germany |
| State | MA |
| City | Somerville |
| Address | 455 Grand Union Boulevard |
| ZIP | 02145 |
| Phone | 339 499 9300 |
| Website | https://www.bluebirdbio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 323 |
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
Q&A For bluebird bio, Inc. Stock
What is a current BLE.MU stock price?
bluebird bio, Inc. BLE.MU stock price today per share is 1.11 EUR.
How to purchase bluebird bio, Inc. stock?
You can buy BLE.MU shares on the Munich exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for bluebird bio, Inc.?
The stock symbol or ticker of bluebird bio, Inc. is BLE.MU.
Which industry does the bluebird bio, Inc. company belong to?
The bluebird bio, Inc. industry is Biotechnology.
How many shares does bluebird bio, Inc. have in circulation?
The max supply of bluebird bio, Inc. shares is 192.74M.
What is bluebird bio, Inc. Price to Earnings Ratio (PE Ratio)?
bluebird bio, Inc. PE Ratio is now.
What was bluebird bio, Inc. earnings per share over the trailing 12 months (TTM)?
bluebird bio, Inc. EPS is -0.59 EUR over the trailing 12 months.
Which sector does the bluebird bio, Inc. company belong to?
The bluebird bio, Inc. sector is Healthcare.